1. Home
  2. Research
  3. Research Groups
  4. Neurodegenerative diseases: therapy development

Neurodegenerative diseases: therapy development

Search for publications

Only original articles, editorials, guidelines.

  • Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G, Baker D.

    Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors

    MULTIPLE SCLEROSIS JOURNAL . 19(14): 1896-1904. Number of citations: 27

    [doi:10.1177/1352458513485982]

  • Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML.

    New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo

    JOURNAL OF MEDICINAL CHEMISTRY . 56(20): 7851-7861. Number of citations: 22

    [doi:10.1021/jm400766k]

  • Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M, Sagredo O, Di Marzo V, Fernández-Ruiz J.

    The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

    CELL DEATH & DISEASE . 4: . Number of citations: 64

    [doi:10.1038/cddis.2013.387]

  • Perucho J, Casarejos MJ, Gómez A, Ruíz C, Fernández-Estevez MÁ, Muñoz MP, de Yébenes JG, Mena MÁ.

    Striatal Infusion of Glial Conditioned Medium Diminishes Huntingtin Pathology in R6/1 Mice

    Plos One . 8(9): . Number of citations: 9

    [doi:10.1371/journal.pone.0073120]

  • Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J.

    Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors

    Neuropharmacology . 71: 282-291. Number of citations: 132

    [doi:10.1016/j.neuropharm.2013.03.027]

  • Gómez del Rio MA, Sánchez-Reus MI, Iglesias I, Pozo MA, García-Arencibia M, Fernández-Ruiz J, García-García L, Delgado M, Benedí J.

    Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease.

    CNS NEUROL DISORD-DR . 12(5): 665-679.

  • Alvarado M, Decara J, Luque MJ, Hernandez-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, Fernández-Ruiz J, Elguero J, Jagerovic N, Serrano A, Goya P, de Fonseca FR.

    Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    BIOORGANIC & MEDICINAL CHEMISTRY . 21(7): 1708-1716. Number of citations: 16

    [doi:10.1016/j.bmc.2013.01.055]

  • Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruíz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruíz J, Meana JJ, Jagerovic N.

    Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties

    ARCHIV DER PHARMAZIE . 346(3): 171-179. Number of citations: 11

    [doi:10.1002/ardp.201200392]

  • Llorente-Folch I, Sahún I, Contreras L, Casarejos MJ, Grau JM, Saheki T, Mena MA, Satrústegui J, Dierssen M, Pardo B.

    AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway

    JOURNAL OF NEUROCHEMISTRY . 124(3): 347-362. Number of citations: 12

    [doi:10.1111/jnc.12096]

  • Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

    Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY . 75(2): 323-333. Number of citations: 195

    [doi:10.1111/j.1365-2125.2012.04341.x]

  • Casarejos MJ, Perucho J, Gomez A, Muñoz MP, Fernandez-Estevez M, Sagredo O, Fernandez Ruiz J, Guzman M, de Yebenes JG, Mena MA.

    Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy

    JOURNAL OF ALZHEIMERS DISEASE . 35(3): 525-539. Number of citations: 64

    [doi:10.3233/JAD-130050]

  • Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Cantarero I, Calzado MA, Bellido ML, Fernandez-Ruiz J, Appendino G, Guaza C, Muñoz E.

    A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis

    JOURNAL OF NEUROIMMUNE PHARMACOLOGY . 7(4): 1002-1016. Number of citations: 82

    [doi:10.1007/s11481-012-9399-3]

  • Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J.

    Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function

    Neuropharmacology . 63(5): 776-783. Number of citations: 96

    [doi:10.1016/j.neuropharm.2012.05.034]

  • Ruiz C, Casarejos MJ, Rubio I, Gines S, Puigdellivol M, Alberch J, Mena MA, de Yebenes JG.

    The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins

    BRAIN RESEARCH . 1459: 100-112. Number of citations: 8

    [doi:10.1016/j.brainres.2012.04.021]

  • de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J.

    Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

    Neuropharmacology . 62(7): 2299-2308. Number of citations: 60

    [doi:10.1016/j.neuropharm.2012.01.030]

  • Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

    Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB1 and CB2 Receptors

    ACS CHEMICAL NEUROSCIENCE . 3(5): 400-406. Number of citations: 58

    [doi:10.1021/cn200114w]

  • Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

    Cannabinoids: novel medicines for the treatment of Huntington's disease.

    Recent patents on CNS drug discovery . 7(1): 41-48.

  • Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DC, Goya P, Reggio PH, Martin MI, Fernández-Ruiz J, Silva AM, Jagerovic N.

    Chromenopyrazoles: Non-psychoactive and Selective CB1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    Chemmedchem . 7(3, SI): 452-463. Number of citations: 26

    [doi:10.1002/cmdc.201100568]